Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P3ZN
|
|||
| Former ID |
DNCL003385
|
|||
| Drug Name |
RDEA3170
|
|||
| Indication | Hyperuricaemia [ICD-11: 5C55.Y] | Phase 2 | [1] | |
| Company |
AstraZeneca
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H16N2O2S
|
|||
| Canonical SMILES |
CC(C)(C(=O)O)SC1=C(C=NC=C1)C2=CC=C(C3=CC=CC=C32)C#N
|
|||
| InChI |
1S/C20H16N2O2S/c1-20(2,19(23)24)25-18-9-10-22-12-17(18)16-8-7-13(11-21)14-5-3-4-6-15(14)16/h3-10,12H,1-2H3,(H,23,24)
|
|||
| InChIKey |
YYBOLPLTQDKXPM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1352792-74-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Urate anion exchanger 1 (URAT1) | Target Info | Modulator | [2] |
| WikiPathways | Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02078219) Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia. U.S. National Institutes of Health. | |||
| REF 2 | The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol. 2013; 14: 164. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.